Gsk (GSK) Cash from Operations (2009 - 2026)

Gsk's Cash from Operations history runs 18 years deep, the most recent figure standing at 1820040839.39 for Q1 2026.

• In Q1 2026, Cash from Operations rose 11.07% year-over-year to 1820040839.39; the TTM figure through Mar 2026 stood at 11988492734.37 (up 33.25% YoY), while the FY2025 annual figure was 11791437934.07, up 17.34% from the prior year.
• Cash from Operations for Q1 2026 stood at 1820040839.39, down from 4966840585.08 in the prior quarter.
• The five-year high for Cash from Operations was 4966840585.08 in Q4 2025, with the low at 348851232.01 in Q1 2023.
• The 5-year median for Cash from Operations is 1820040839.39 (2026), against an average of 2353476135.63.
• The sharpest annual moves came in 2023 and 2024: Cash from Operations plunged 88.21% in 2023, then jumped 309.44% in 2024.
• Gsk's Cash from Operations stood at 3990302148.51 in 2022, then sank by 40.68% to 2366876645.43 in 2023, then jumped by 50.54% to 3563001106.15 in 2024, then soared by 39.4% to 4966840585.08 in 2025, then tumbled by 63.36% to 1820040839.39 in 2026.
• Business Quant data shows GSK's Cash from Operations at 1820040839.39 in Q1 2026, 4966840585.08 in Q4 2025, and 1638610203.75 in Q1 2025.